Oncologists should ask in advance about what young patients and their parents want to be told about changing prognoses, a new qualitative study finds
Pediatric oncologists must regularly have some of the hardest conversations in the medical profession with patients and parents: Will the child survive? For how long? Will treatment be painful?
Yet they infrequently ask patients and parents about their preferences for receiving information about prognoses before initiating difficult discussions. Indeed, studies have found a mismatch between what pediatric oncologists know about a child’s prognosis and what they communicate to patients and families at the bedside or in the office.
A qualitative study involving 85 participants — 25 patients, 40 parents and 20 oncologists — examined how much information the first two groups wanted to hear about poor prognoses and whether they wanted to discuss that decision with their doctor in advance, and how the oncologists felt about both.
Most members of the three groups strongly agreed that sharing more information is better, and patients and parents — and some oncologists — believed that discussing communication preferences in advance is important, according to study findings published April 16, 2025, in JAMA Network Open.
Caroline Christianson, M.D.
First author Caroline Christianson, M.D., a pediatric hematology and oncology fellow at NYU Langone Health in New York City, and colleagues at St. Jude Children’s Research Hospital in Memphis, Tennessee, where all the patients had spent some time, and other institutions around the U.S., recruited three groups of participants for single interviews: patients aged 12 to 25 diagnosed with cancer with an estimated survival of 50% or less; parents or caregivers of children who had cancer with a poor prognosis, as well as parents whose children had died six to 24 months before; and oncologists from six pediatric cancer programs in five states.
There were two sets of targeted interview prompts and probes for patients and parents: "Do you want to know information about prognosis? Why or why not?” and “Should a doctor ask you ahead of time about what information you want to hear?”
Interviewers were prompted to ask oncologists one basic question (with follow-ups): “Do you routinely ask patients or families what information they want to hear before sharing information about prognosis?”
Nearly all patients and parents wanted to hear information about prognosis.
Most parents and oncologists also advocated for disclosure of diagnosis even if not requested or desired by patients or parents. At least some patients agreed, with younger children less likely to say oncologists should share information even if they didn’t want to know
Most patients and parents also agreed that doctors should ask ahead of time about what information they wanted to hear (opinions were mixed among oncologists).
Patients, parents and oncologists also recommended some strategies for eliciting prognostic communication preferences.
The authors wrote that their findings “demonstrate that patients and caregivers are open to discussing prognostic communication preferences and that oncologists also recognize the potential value in this communication approach, even as they rarely engage in it.”
They said they hope that their findings “may empower clinicians at the bedside to consider broaching conversations about prognostic communication preferences in advance of disease reevaluation discussions, recognizing that patients and families may welcome these conversations.”
Analysis Finds Brukinsa May Provide Costs Savings Over Imbruvica in CLL
April 14th 2025In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.
Read More
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
April 8th 2025About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related leukemias are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML).
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
CAR T-Cell Therapy Cuts Costs, Reduces Treatment in Mantle Cell Lymphoma
March 13th 2025In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
Read More